Leukocyte-Rich vs. Leukocyte-Poor PRP: The White Cell Question That Changes Everything

Ask three clinics what platelet-rich plasma is and you will get three answers that sound the same. Spin the patient's blood, concentrate the platelets, inject the result. What that summary hides is a fork in the road that happens inside the centrifuge: whether the final product keeps the white blood cells or removes them. That single variable, leukocyte concentration, may explain more of the conflicting PRP research than any other factor, and most patients never hear about it.

What the two preparations actually are

Leukocyte-rich PRP, often abbreviated LR-PRP, concentrates white blood cells, especially neutrophils, above baseline blood levels, sometimes three to five times higher. Leukocyte-poor PRP, or LP-PRP, uses a different spin protocol or a filtration step to strip most white cells out while keeping platelet concentration elevated. Both products can legitimately be labeled PRP. Both come from the same tube of blood. Their downstream biology diverges sharply.

The reason is what neutrophils do when activated. They release catabolic enzymes, including matrix metalloproteinases and elastase, along with reactive oxygen species and inflammatory cytokines such as interleukin-1 beta and tumor necrosis factor alpha. In a wound that needs debris cleared, that is useful. Inside a joint capsule lined with sensitive synovial tissue, it can amplify inflammation rather than resolve it.

Why joints and tendons may want different recipes

The most consistent signal in the comparative literature involves knee osteoarthritis. Laboratory studies exposing cartilage and synovial cells to both preparations have repeatedly found that leukocyte-rich formulas provoke more inflammatory gene expression and more cell stress. Clinically, this tracks with reports that LR-PRP injections into arthritic knees produce more short-term swelling and post-injection pain. Several meta-analyses of randomized trials have leaned toward leukocyte-poor preparations for osteoarthritis symptom relief, which is why many sports medicine physicians now default to LP-PRP for intra-articular work.

Tendons are a different environment. Chronic tendinopathy, the degenerative condition behind stubborn tennis elbow and patellar tendon pain, is often described as a failed healing response. The tissue is stuck: disorganized collagen, poor blood supply, and notably little active inflammation. One school of thought holds that these tendons need a controlled inflammatory restart, and that the neutrophils and monocytes in LR-PRP supply exactly that stimulus. The best-known trials in lateral epicondylitis, the ones that put PRP on the map for elbow pain, used leukocyte-rich preparations. Head-to-head data remain thinner than anyone would like, but the working consensus among many musculoskeletal specialists runs roughly: leukocyte-poor for joints, leukocyte-rich considered for chronic tendinopathy, with honest uncertainty at the edges.

The mechanism, in plain terms

Platelets carry alpha granules loaded with growth factors: PDGF, TGF-beta, VEGF, IGF-1 and others. These signal resident cells to proliferate, recruit repair cells, and build new blood vessels and matrix. That is the anabolic side of PRP, and both preparations deliver it. White cells add a second, catabolic and immunologic layer on top. Whether that layer helps or hurts appears to depend on the target tissue's baseline state. Degenerated, quiet tendon may benefit from the wake-up call. Already-irritated synovium and cartilage generally do not.

What this means for the research mess

When you read that PRP studies are contradictory, remember that a trial using LR-PRP in knees and a trial using LP-PRP in knees are not testing the same intervention. Add variation in platelet dose, activation method, injection volume, and number of sessions, and the literature becomes a comparison of dozens of different products under one name. Reviews that separate trials by leukocyte content find cleaner patterns than reviews that lump everything together. This is slowly improving: newer studies increasingly report full cell counts of the injected product, a practice sometimes called minimum reporting standards, and journals are pushing for it.

Questions worth asking before treatment

A patient considering PRP for a joint or tendon can reasonably ask three things. First, is the preparation leukocyte-rich or leukocyte-poor, and why was that chosen for this specific tissue? Second, what platelet concentration does the system typically achieve? Doses below roughly two to three times baseline may underdeliver, while some evidence suggests very high concentrations offer no added benefit. Third, will the clinic document what was actually injected? A provider who cannot answer the white cell question is running a protocol, not practicing the biology.

The bottom line

PRP is not one therapy. It is a family of blood-derived products whose behavior hinges on preparation details, and leukocyte content sits at the top of that list. The evidence, while incomplete, points toward matching the formula to the tissue: quieter, leukocyte-poor plasma for inflamed joints, and possibly the more provocative leukocyte-rich version for degenerated tendons that have stopped trying to heal. Neither is universally better. The right question is never whether PRP works, but which PRP, prepared how, injected where.

Related reading: How PRP is made, and why preparation changes everything.

Further reading: Histological effects of intra-articular allogeneic leukocyte-rich and leukocyte-poor platelet-rich plasma in healthy rabbit knees: an exploratory study (BMC Res Notes 2026); Leukocyte-Rich Platelet-Rich Plasma Is Predominantly Anti-inflammatory Compared With Leukocyte-Poor Platelet-Rich Plasma in Patients With Mild-Moderate Knee Osteoarthritis: A Prospective, Descriptive Laboratory Study (Am J Sports Med 2023); Parecoxib alleviates the inflammatory effect of leukocyte-rich platelet-rich plasma in normal rabbit tendons (BMC Musculoskelet Disord 2020).